Internal Medicine, Hematology & Oncology · New City, NY
NPI
1932143518
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
10 Esquire Rd, Suite 6
New City, NY, 10956
Phone (845) 634-2727
Groups this clinician bills Medicare through
Medicare paid, 2024
$632K
114,744 services
Medicare patients, 2024
938
Average age 76
Drug cost, 2024
$5.9M
1,376 prescriptions
Company payments, 2025
$945
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Seth A Benkel was code J1756 (injection, iron sucrose, 1 mg), 38,800 times for 51 patients. In total Seth A Benkel billed 114,744 services in 67 codes, and Medicare paid $632K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 38,800 | 51 | $0.13 | $4,966 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,860 | 46 | $0.00 | $1.72 |
| 82784 Immunoassay | Office | 3,028 | 709 | $9.08 | $28K |
| 85025 Blood Count | Office | 2,952 | 904 | $7.55 | $22K |
| 36415 Venipuncture Blood Collection | Office | 2,943 | 899 | $4.88 | $14K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,560 | 22 | $0.00 | $0.53 |
| 80053 Clinical Chemistry | Office | 1,925 | 877 | $10.32 | $20K |
| 83615 Clinical Chemistry | Office | 1,924 | 877 | $5.90 | $11K |
| 82728 Clinical Chemistry | Office | 1,699 | 867 | $13.32 | $23K |
| 83540 Clinical Chemistry | Office | 1,699 | 867 | $6.32 | $11K |
| 83550 Clinical Chemistry | Office | 1,698 | 866 | $8.55 | $15K |
| 82607 Clinical Chemistry | Office | 1,673 | 866 | $14.73 | $25K |
| 82746 Clinical Chemistry | Office | 1,673 | 866 | $14.37 | $24K |
| 99214 Office E&M - Established | Office | 1,297 | 652 | $116.40 | $151K |
| J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 1,214 | 25 | $1.25 | $1,523 |
By year: 2022 $690K for 141,630 services; 2023 $582K for 135,085 services; 2024 $632K for 114,744 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82784 Immunoassay | 3,028 | 709 | $9.08 | $28K |
| 85025 Blood Count | 2,952 | 904 | $7.55 | $22K |
| 36415 Venipuncture Blood Collection | 2,943 | 899 | $4.88 | $14K |
| 80053 Clinical Chemistry | 1,925 | 877 | $10.32 | $20K |
| 83615 Clinical Chemistry | 1,924 | 877 | $5.90 | $11K |
| 82728 Clinical Chemistry | 1,699 | 867 | $13.32 | $23K |
| 83540 Clinical Chemistry | 1,699 | 867 | $6.32 | $11K |
| 83550 Clinical Chemistry | 1,698 | 866 | $8.55 | $15K |
| 82746 Clinical Chemistry | 1,673 | 866 | $14.37 | $24K |
| 82607 Clinical Chemistry | 1,673 | 866 | $14.73 | $25K |
Medicare prescription drug claims, 2024
In 2024, the drug Seth A Benkel prescribed most often to Medicare patients was Xarelto (Rivaroxaban), with 275 prescriptions and refills. In total Seth A Benkel wrote 1,376 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | 275 | 669 | 77 | $365K |
| Eliquis Apixaban | 225 | 499 | 61 | $283K |
| Warfarin Sodium Generic | 105 | 274 | 24 | $1,354 |
| Procrit Epoetin Alfa | 56 | 56 | 30 | $230K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 53 | 54 | Under 11 | $888K |
| Bortezomib Generic | 50 | 50 | Under 11 | $91K |
| Reblozyl Luspatercept-Aamt | 44 | 44 | Under 11 | $659K |
| Retacrit Epoetin Alfa-Epbx | 44 | 44 | 20 | $73K |
| Hydroxyurea Generic | 43 | 115 | 14 | $1,514 |
| Enoxaparin Sodium Generic | 38 | 38 | Under 11 | $5,427 |
| Prednisone Generic | 35 | 61 | Under 11 | $308 |
| Anastrozole Generic | 33 | 89 | Under 11 | $749 |
| Imbruvica Ibrutinib | 30 | 30 | Under 11 | $490K |
| Ninlaro Ixazomib Citrate | 27 | 27 | Under 11 | $331K |
| Sprycel Dasatinib | 21 | 21 | Under 11 | $356K |
Brand drugs: 923 claims; generic drugs: 453 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Seth A Benkel $945 ($945 in general payments such as food, travel and fees) from 17 companies. The largest payer was Novartis Pharmaceuticals Corporation with $177.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 7 | $177 |
| Abbvie Inc. ABBV | 7 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $87.78 |
| Merck Sharp & Dohme LLC MRK | 3 | $81.41 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $81.17 |
| Janssen Biotech, Inc. JNJ | 2 | $55.52 |
| Incyte Corporation INCY | 2 | $50.52 |
| Genentech USA, Inc. ROG.SW | 2 | $42.44 |
| GlaxoSmithKline, LLC. GSK | 1 | $31.69 |
| Karyopharm Therapeutics Inc. KPTI | 1 | $29.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.